Literature DB >> 20166928

Novel natural and synthetic ligands of the endocannabinoid system.

Lumír O Hanus1, Raphael Mechoulam.   

Abstract

In this review we describe recent advances in the chemistry of novel CB(1)/CB(2) agonists, CB(1) antagonists, selective CB(2) agonists, fatty acid amide hydrolase inibitors, monoglyceride (MGL) and diglyceride (DAGL) inhibitors and cannabinoid-type agonists and antagonists of non CB(1)/CB(2) receptors. In view of recent interest in the activities of fatty acid amides of amino acids (N-acyl amino acids) a list of this type of compounds was compiled and is presented as a Table. We conclude that further synthetic work based on both the plant cannabinoids and on the endocannabinoids may lead to novel therapeutics and that the identification and the elucidation of the biological profile of the myriad of endogenous N-acyl amino acids and related compounds may enhance the already wide spectrum of lipidomics.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20166928     DOI: 10.2174/092986710790980096

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  12 in total

1.  Chromenopyrazoles: non-psychoactive and selective CB₁ cannabinoid agonists with peripheral antinociceptive properties.

Authors:  Jose Cumella; Laura Hernández-Folgado; Rocio Girón; Eva Sánchez; Paula Morales; Dow P Hurst; Maria Gómez-Cañas; Maria Gómez-Ruiz; Diana C G A Pinto; Pilar Goya; Patricia H Reggio; María Isabel Martin; Javier Fernández-Ruiz; Artur M S Silva; Nadine Jagerovic
Journal:  ChemMedChem       Date:  2012-02-02       Impact factor: 3.466

2.  Effects of the endogenous cannabinoid anandamide on voltage-dependent sodium and calcium channels in rat ventricular myocytes.

Authors:  Lina T Al Kury; Oleg I Voitychuk; Keun-Hang Susan Yang; Faisal T Thayyullathil; Petro Doroshenko; Ali M Ramez; Yaroslav M Shuba; Sehamuddin Galadari; Frank Christopher Howarth; Murat Oz
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

3.  Design of a Potent CB1 Receptor Antagonist Series: Potential Scaffold for Peripherally-Targeted Agents.

Authors:  Robert L Dow; Philip A Carpino; Denise Gautreau; John R Hadcock; Philip A Iredale; Dawn Kelly-Sullivan; Jeffrey S Lizano; Rebecca E O'Connor; Steven R Schneider; Dennis O Scott; Karen M Ward
Journal:  ACS Med Chem Lett       Date:  2012-03-21       Impact factor: 4.345

4.  Endocannabinoids stimulate human melanogenesis via type-1 cannabinoid receptor.

Authors:  Mariangela Pucci; Nicoletta Pasquariello; Natalia Battista; Monia Di Tommaso; Cinzia Rapino; Filomena Fezza; Michela Zuccolo; Roland Jourdain; Alessandro Finazzi Agrò; Lionel Breton; Mauro Maccarrone
Journal:  J Biol Chem       Date:  2012-03-19       Impact factor: 5.157

Review 5.  Is lipid signaling through cannabinoid 2 receptors part of a protective system?

Authors:  P Pacher; R Mechoulam
Journal:  Prog Lipid Res       Date:  2011-02-02       Impact factor: 16.195

6.  Energetic metabolism and human sperm motility: impact of CB₁ receptor activation.

Authors:  A Barbonetti; M R C Vassallo; D Fortunato; S Francavilla; M Maccarrone; F Francavilla
Journal:  Endocrinology       Date:  2010-10-20       Impact factor: 4.736

7.  Endocannabinoids are expressed in bone marrow stromal niches and play a role in interactions of hematopoietic stem and progenitor cells with the bone marrow microenvironment.

Authors:  Shuxian Jiang; Radoslaw Zagozdzon; Meritxell Alberich Jorda; Kalindi Parmar; Yigong Fu; John S Williams; Jodi Anne T Wood; Alexandros Makriyannis; Naheed Banu; Shalom Avraham; Jerome E Groopman; Hava Karsenty Avraham
Journal:  J Biol Chem       Date:  2010-09-07       Impact factor: 5.157

Review 8.  Endocannabinoids in synaptic plasticity and neuroprotection.

Authors:  Jian-Yi Xu; Chu Chen
Journal:  Neuroscientist       Date:  2014-02-25       Impact factor: 7.519

Review 9.  Modulating the endocannabinoid system in human health and disease--successes and failures.

Authors:  Pál Pacher; George Kunos
Journal:  FEBS J       Date:  2013-04-22       Impact factor: 5.542

10.  The natural product magnolol as a lead structure for the development of potent cannabinoid receptor agonists.

Authors:  Alexander Fuchs; Viktor Rempel; Christa E Müller
Journal:  PLoS One       Date:  2013-10-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.